• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Research Brief on 6-chloro-N-(2-phenylethyl)pyridazin-3-amine (CAS: 919522-46-6): Recent Advances and Applications

The compound 6-chloro-N-(2-phenylethyl)pyridazin-3-amine (CAS: 919522-46-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This pyridazine derivative is being explored for its potential therapeutic applications, particularly in the modulation of specific biological pathways. Recent studies have focused on its synthesis, structural optimization, and biological activity profiling, making it a promising candidate for drug development.

One of the key areas of interest is the compound's role as a kinase inhibitor. Preliminary in vitro studies have demonstrated its ability to selectively target certain kinases involved in inflammatory and oncogenic pathways. Researchers have employed molecular docking and kinetic assays to elucidate its binding affinity and mechanism of action, revealing a competitive inhibition pattern at the ATP-binding site of the target kinases. These findings suggest potential applications in treating diseases such as rheumatoid arthritis and certain cancers.

Structural modifications of 6-chloro-N-(2-phenylethyl)pyridazin-3-amine have been investigated to enhance its pharmacokinetic properties. Recent work has focused on improving its solubility and metabolic stability while maintaining its biological activity. Structure-activity relationship (SAR) studies have identified critical functional groups that contribute to its efficacy, providing a foundation for further optimization. These efforts aim to address challenges related to bioavailability and off-target effects, which are common hurdles in drug development.

In addition to its kinase inhibitory properties, recent research has explored the compound's potential as a modulator of G-protein-coupled receptors (GPCRs). Early-stage studies indicate that it may interact with specific GPCR subtypes, opening new avenues for therapeutic intervention in neurological and cardiovascular disorders. However, further validation through in vivo models is required to confirm these preliminary observations and assess the compound's safety profile.

The synthesis of 6-chloro-N-(2-phenylethyl)pyridazin-3-amine has also seen advancements, with recent publications reporting more efficient and scalable routes. Green chemistry approaches, such as catalytic methods and solvent-free reactions, have been employed to reduce environmental impact and improve yield. These developments are crucial for enabling large-scale production and facilitating future clinical studies.

In conclusion, 6-chloro-N-(2-phenylethyl)pyridazin-3-amine represents a versatile scaffold with multiple therapeutic potentials. Ongoing research continues to uncover its mechanisms of action and optimize its properties for clinical applications. As the field progresses, this compound may emerge as a valuable tool for addressing unmet medical needs in various disease areas.

• 919522-44-4(3-Pyridazinamine, 6-chloro-N-[(3,4-dichlorophenyl)methyl]-)
• 242802-86-4(1,3-Propanediamine,N'-(6-chloro-3-pyridazinyl)-N-methyl-N-(phenylmethyl)-)
• 3603-52-9(2-[(6-chloropyridazin-3-yl)amino]-1-phenylethanol;hydrochloride)
• 100223-83-4(Pyridazine, 3-chloro-6-[3-(4-chlorophenyl)-1-piperidinyl]-)
• 100223-77-6(Pyridazine, 3-chloro-6-[4-(4-methylphenyl)-1-piperidinyl]-)
• 1496-85-1(N-benzyl-6-chloropyridazin-3-amine)
• 919522-37-5(6-chloro-N-[(4-methylphenyl)methyl]pyridazin-3-amine)
• 100224-31-5(Pyridazine, 3-chloro-6-[3-(2,3-dimethylphenyl)-1-piperidinyl]-)
• 100224-41-7(Pyridazine, 3-chloro-6-[3-(3-methylphenyl)-1-pyrrolidinyl]-)
• 100240-43-5(Pyridazine, 3-chloro-6-(4-phenyl-1-piperidinyl)-)